StockData

China SXT Pharmaceuticals, Inc. (SXTC) stock

SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30
$2.83−0.03 (-1.05%)

Close on Nov 18, 2026Market cap $2.71MP/E –Yield –

China SXT Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2026 it was $248.70K, down 32.3% from the year before. The highest annual figure on record is $4.61M in fiscal 2019.

Annual gross profit

PeriodPeriod endValueChange
FY2026Mar 31, 2026$248.70K-32.3%
FY2025Mar 31, 2025$367.43K-33.7%
FY2024Mar 31, 2024$553.97K+30.0%
FY2023Mar 31, 2023$426.27K-65.9%
FY2022Mar 31, 2022$1.25M-55.9%
FY2021Mar 31, 2021$2.84M+5.0%
FY2020Mar 31, 2020$2.70M-41.4%
FY2019Mar 31, 2019$4.61M+35.6%
FY2018Mar 31, 2018$3.40M+47.1%
FY2017Mar 31, 2017$2.31M–

More China SXT Pharmaceuticals figures

See a number that looks wrong?